Abstract: A cephalosporin C acylase from Pseudomonas diminuta N-176 is characterized by its ability to catalyze the conversion of cephalosporin C, glutaryl 7-ACA, adipyl 7-ACA, succinyl 7-ACA, N-acetylcephalosporin, N-benzoylcephalosporin C and cephalothin into 7-aminocephalosporanic acid. The enzyme contains an .alpha.-subunit having a molecular weight of 26 kDA and a .beta.-subunit having a molecular weight of 58 kDa. A method for the recombinant production of the present cephalosporin C acylase in Escherichia coli is provided.

Abstract: A GL-7ACA acylase having the following characteristics:(a) has ability to catalyze the enzymatic conversion of glutaryl 7-ACA, adipyl 7-ACA, and succinyl 7-ACA, into 7-aminocephalosporanic acid,(b) has a molecular weight of 70,000 dalton (SDS-PAGE) and(c) has N-terminal amino acid sequence (sea in No: 1) thereof: Gln-Ser-Glu-Gln-Glu-Lys-Ala-Glu-Glu-.A process for producing GL-7ACA acylase is also provided.

Abstract: A GL-7ACA acylase having the following characteristics:(a) has ability to catalyze the enzymatic conversion of glutaryl 7-ACA, adipyl 7-ACA, and succinyl 7-ACA, into 7-aminocephalosporanic acid,(b) has a molecular weight of 70,000 dalton (SDS-PAGE) and(c) has N-terminal amino acid sequence (SEQ ID NO: 1) thereof: Gln-Ser-Glu-Gln-Glu-Lys-Ala-Glu-Glu-.A process for producing GL-7ACA acylase is also provided.

Abstract: A cephalosporin C acylase from Pseudomonas diminuta N-176 is disclosed as well as the recombinant production of this enzyme in E. coli. The enzyme is characterized by the ability to catalyze the conversion of cephalosporin C, gultaryl 7-ACA, apidyl 7-ACA, succinyl 7-ACA, N-acetylcephalosporin C, N-benzoylcephalosporin C, and cephalothin into 7-aminocephalosporanic acid and is composed of an .alpha.-subunit with a molecular weight of 26,000 daltons and a .beta.-subunit with a molecular weight of 58,000 daltons.

Abstract: FR-900493 is a compound of molecular formula C.sub.20 H.sub.33 N.sub.5 O.sub.11 which may be recovered from Bacillus cultures, possesses antimicrobial activity, and may be used for the treatment and prevention of infectious diseases in humans and animals.

Abstract: New nitro aliphatic compounds useful as antithrombotic and antihypertensing agents are disclosed.

Abstract: The invention relates to a method for treatment of carcinoma or sarcoma tumor in mammals which comprises administering to said mammal an effective amount of a tetracyclo compound of the formula: ##STR1## in which R.sup.1 is formyl, protected formyl, hydroxymethyl, protected hydroxymethyl, arylaminomethyl, carboxy, protected carboxy, aryliminomethyl, hydroxyiminomethyl, alkoxyiminomethyl, acyloxyiminomethyl, semicarbazonomethyl or arylsemicarbazonomethyl,R.sup.2 is hydroxy, alkoxy, or protected hydroxy,R.sup.3 is hydrogen and R.sup.4 is methyl, hydroxymethyl or protected hydroxymethyl, orR.sup.3 and R.sup.4 are combined together to form methylene or oxo,R.sup.5 is hydroxy, alkoxy or protected hydroxy, andR.sup.6 is hydrogen, imino-protective group or alkyl,and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to compounds of antihypertensive and antithrombotic activity of the formula or its pharmaceutically acceptable salt: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, or lower alkoxyphenyl,R.sup.2 is hydrogen or lower alkyl,R.sup.4 is lower alkyl,R.sup.6 is hydrogen or lower alkyl,R.sup.7 is lower alkyl which is optionally substituted by hydroxy or lower alkanoyloxy, andR.sup.10 is hydrogen or lower alkyl which is optionally substituted by carboxy or esterified carboxy.

Abstract: New nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

Abstract: New Nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

Abstract: A biologically pure culture of Streptomyces sandaensis which is capable of producing an antitumor and antimicrobial compound, designated FR-900482 substance, is disclosed.

Abstract: This invention relates to a biologically active WS-7739-A substance and a biologically active WS-7739-B substance which have pharmacological activities and are useful for the treatment of asthma, thrombosis and the alike.

Abstract: New tetracyclo compounds of the formula: ##STR1## in which R.sup.1 is formyl, protected formyl, hydroxymethyl, protected hydroxymethyl, arylaminomethyl, carboxy, protected carboxy or substituted iminomethyl,R.sup.2 is hydroxy, alkoxy or protected hydroxy,R.sup.3 is hydrogen and R.sup.4 is methyl, hydroxymethyl or protected hydroxymethyl, orR.sup.3 and R.sup.4 are combined together to form methylene or oxo,R.sup.5 is hydroxy, alkoxy or protected hydroxy, andR.sup.6 is hydrogen, imino-protective group or alkyl,and pharmaceutically acceptable salts thereof, which have pharmacological activities such as antitumor activity, antimicrobial activity, and the like, and a process for their production and a pharmaceutical composition containing the same.

Abstract: Novel compounds designated as WS 6049-A and WS 6049-B are disclosed, as well as compositions containing the compounds thereof, a method of treating microbial infections, a method of prolonging the survival time of the patient with lymphocytic leukemia by administering the compounds thereof, and a process for making the WS 6049 substances, are disclosed. As indicated above, the novel compounds have antimicrobial and antileukemic activities which make them useful against a variety of pathogenic microorganisms and leukemic tumors.